HCA Healthcare (HCA) shares jumped to an all-time high Tuesday after the health-care services provider posted better-than-expected earnings and boosted its guidance, as the company reported bringing in more patients.
HCA Healthcare (HCA) increases its 2024 EPS in the range of $21.60-$22.8, the midpoint implying growth of 17% from the 2023 figure.
Although the revenue and EPS for HCA (HCA) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
HCA Healthcare (HCA) came out with quarterly earnings of $5.50 per share, beating the Zacks Consensus Estimate of $4.97 per share. This compares to earnings of $4.29 per share a year ago.
Hospital giant raises full-year guidance amid growth in admissions, inpatient surgeries
HCA Healthcare raised its annual profit forecast on Tuesday, after beating Wall Street estimates for quarterly earnings, sending shares of the hospital operator up nearly 7% before the bell.
Here is how HCA Healthcare (HCA) and AnaptysBio, Inc. (ANAB) have performed compared to their sector so far this year.
HCA Healthcare, Inc. will report earnings on Tuesday, July 23rd. I expect HCA to have a strong quarter based on reaffirmed guidance, industry trends, and consensus revisions upward. Multiple valuation methods signal HCA is fairly priced, while industry trends suggest balanced upside and downside. I continue to rate HCA a hold.
HCA Healthcare's (HCA) second-quarter earnings are likely to benefit from improved admissions and payer mix, partially offset by rising operating expenses.
HCA (HCA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
These healthcare businesses are booming. Vertex Pharmaceuticals is raking in approvals, cash, and profits.
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.